Growth Metrics

Quest Diagnostics (DGX) Liabilities and Shareholders Equity (2016 - 2026)

Quest Diagnostics' Liabilities and Shareholders Equity history spans 18 years, with the latest figure at $16.7 billion for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 5.55% to $16.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $65.1 billion, a 5.07% increase, with the full-year FY2025 number at $16.2 billion, changed 0.45% from a year prior.
  • Liabilities and Shareholders Equity hit $16.7 billion in Q1 2026 for Quest Diagnostics, up from $16.2 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for DGX hit a ceiling of $16.7 billion in Q1 2026 and a floor of $12.8 billion in Q1 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $14.6 billion across 5 years, with a median of $14.0 billion in 2024.
  • Biggest five-year swings in Liabilities and Shareholders Equity: dropped 5.69% in 2022 and later increased 19.38% in 2024.
  • Tracing DGX's Liabilities and Shareholders Equity over 5 years: stood at $12.8 billion in 2022, then rose by 9.23% to $14.0 billion in 2023, then grew by 15.2% to $16.2 billion in 2024, then rose by 0.45% to $16.2 billion in 2025, then rose by 2.76% to $16.7 billion in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for DGX at $16.7 billion in Q1 2026, $16.2 billion in Q4 2025, and $16.2 billion in Q3 2025.